Filtered By:
Condition: Thrombosis
Drug: Cilostazol
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 32 results found since Jan 2013.
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention
AbstractAlthough potent P2Y12 inhibitor-based dual antiplatelet therapy (DAPT) has replaced clopidogrel-based therapy as the standard treatment in patients with acute myocardial infarction (AMI), there is a concern about the risk of bleeding in East Asian patients. We compared the efficacy and safety of cilostazol-based triple antiplatelet therapy (TAT) with potent P2Y12 inhibitor-based DAPT in Korean patients. A total of 4152 AMI patients who underwent percutaneous coronary intervention (PCI) in the Korea Acute Myocardial Infarction Registry were analyzed retrospectively. Patients were divided into two groups: the TAT gro...
Source: Heart and Vessels - April 7, 2020 Category: Cardiology Source Type: research
The Role of Platelets in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics
Prostaglandins Other Lipid Mediat. 2023 Jul 19:106766. doi: 10.1016/j.prostaglandins.2023.106766. Online ahead of print.ABSTRACTPlatelets are one of the key mediators in thrombosis as well as in the progression of many diseases. An increase in platelet activation and a decrease in platelet count is associated with a plethora of liver diseases. In non-alcoholic fatty liver disease (NAFLD), platelets are highly activated and participate in the disease progression by enhancing the pro-thrombotic and pro-inflammatory state. Some altered platelet parameters such as mean platelet volume, plateletcrits, and platelet distribution ...
Source: Atherosclerosis - July 21, 2023 Category: Cardiology Authors: Malladi Navya Md Jahangir Alam Subir K Maulik Sanjay K Banerjee Source Type: research
